EUCTR2007-004219-75-IT进行中（未招募）不适用
Open-label, randomized, controlled, multicenter phase III study investigating cetuximab in combination with capecitabine (Xeloda, X) and cisplatin (P) versus XP alone as first-line treatment for subjects with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction - EXPAND (Erbitux in combination with Xeloda
相关药物
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- Merck KGaA
- 入组人数
- 870
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Written informed consent before any study-related activities are carried out Age ≥ 18 years Histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction (AEG types I-III according to Siewert classification) Archived tumor material sample for at least subsequent standardized EGFR expression assessment Investigators must make sure in advance that appropriate archived tumor material is available from a potentially eligible subject, and that a sample can be shipped to a central repository if the subject agrees to participate. Unresectable advanced (M0) or unresectable metastatic (M1) disease If unresectable advanced disease, at least one measurable locoregional lymph node or other measurable extraluminal tumor lesion ≥ 2cm (independent of whether measured by conventional techniques or spiral CT scan) must be documented. At least one radiographically documented measurable lesion in a previously non-irradiated area according to RECIST, i.e. this lesion must be adequately measurable in at least one dimension (longest diameter to be recorded) as ≥ 2cm by conventional techniques or ≥ 1 cm by spiral CT scan. Primary tumor site will be considered as a nonmeasurable lesion only. ECOG-performance status 0-1 Estimated life expectancy > 12 weeks Medically accepted contraception (if the risk of conception exists) GFR ≥ 60mL/min (Cockroft-Gault formula) ASAT ≤ 2.5 x ULN and ALAT ≤ 2.5 x ULN Bilirubin ≤ 3 x ULN ANC ≥ 1.5 x 109/L Platelets ≥ 100 x 109/L Hemoglobin ≥ 10 g/dL (without transfusions) Sodium and potassium within normal limits or ≤ 10% above or below (supplementation permitted)
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Prior chemotherapy - however: Previous (neo-)adjuvant (radio-)chemotherapy allowed if finished > 1 year prior to start of study treatment and no more than 300 mg/m2 cisplatin has been administered Prior treatment with an antibody or molecule targeting EGFR- and/or VEGFR-related signaling pathways Brain metastasis and/or leptomeningeal disease (known or suspected) Radiotherapy (except localized radiotherapy for pain relief), major surgery or any investigational drug in the 30 days before the start of study treatment Concurrent chronic systemic immune or hormone therapy not indicated in this study protocol except for physiologic replacement Clinically relevant coronary artery disease (NYHA functional angina classification III/IV), congestive heart failure (NYHA III/IV), clinically relevant cardiomyopathy, history of myocardial infarction in the last 12 months, or high risk of uncontrolled arrhythmia Active hepatitis B or C Chronic diarrhea or short bowel syndrome Presence of any contraindication to treatment with cetuximab, capecitabine and cisplatin including: - Known hypersensitivity to capecitabine, fluorouracil, cisplatin, cetuximab or to any of the excipients of these drugs - Known dihydropyrimidine dehydrogenase (DPD) deficiency - Subjects with hereditary problems of galactose intolerance, the Lapp lactase deficiency or glucosegalactose malabsorption - Current treatment with sorivudine or its chemically related analogues, such as brivudine - Symptomatic peripheral neuropathy NCI-CTC AE grade ≥ 2 and/or ototoxicity NCI-CTC AE grade ≥ 2, except if due to trauma or mechanical impairment due to tumor mass Pregnancy or lactation period Concurrent treatment with a non-permitted drug Treatment in another clinical study within the past 30 days Previous malignancy other than gastric cancer in the last 5 years except basal cell cancer of the skin or preinvasive cancer of the cervix Medical or psychological conditions that would not permit the subject to complete the study or sign informed consent Legal incapacity or limited legal capacity Significant disease which, in the investigator?s opinion, would exclude the subject from the study
研究者
相似试验
进行中（未招募）
不适用
Open-label, randomized, controlled, multicenter phase III study investigating cetuximab in combination with capecitabine (Xeloda, X) and cisplatin (P) versus XP alone as first-line treatment for subjects with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction. - EXPANDAdvanced esophago-gastric cancerEUCTR2007-004219-75-NLMerck KGaA870
进行中（未招募）
不适用
Open-label, randomized, controlled, multicenter phase III study investigating cetuximab in combination with capecitabine (Xeloda, X) and cisplatin (P) versus XP alone as first-line treatment for subjects with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction. - EXPANDAdvanced esophago-gastric cancerEUCTR2007-004219-75-BGMerck KGaA870
进行中（未招募）
1 期
Open-label, randomized, controlled, multicenter phase III study investigating cetuximab in combination with capecitabine (Xeloda, X) and cisplatin (P) versus XP alone as first-line treatment for subjects with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction. - EXPANDAdvanced esophago-gastric cancerEUCTR2007-004219-75-FRMerck KGaA
进行中（未招募）
不适用
Open-label, randomized, controlled, multicenter phase III study investigating cetuximab in combination with capecitabine (Xeloda, X) and cisplatin (P) versus XP alone as first-line treatment for subjects with advanced gastric adenocarcinoma including adenocarcinoma of the gastroesophageal junction. - EXPANDAdvanced esophago-gastric cancerEUCTR2007-004219-75-GRMerck KGaA870
进行中（未招募）
1 期
Clinical trial to investigate cetuximab in combination with capecitabine and cisplatin versus capecitabine and cisplatin alone as first-line treatment for patients with advanced gastric cancer.Advanced esophago-gastric cancerMedDRA version: 14.0Level: PTClassification code 10017758Term: Gastric cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2007-004219-75-BEMerck KGaA870